(NASDAQ: AVXL) Anavex Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.23%.
Anavex Life Sciences's earnings in 2026 is -$39,947,000.On average, 5 Wall Street analysts forecast AVXL's earnings for 2026 to be -$30,720,688, with the lowest AVXL earnings forecast at -$29,970,047, and the highest AVXL earnings forecast at -$31,137,711. On average, 5 Wall Street analysts forecast AVXL's earnings for 2027 to be -$13,233,527, with the lowest AVXL earnings forecast at -$49,950,078, and the highest AVXL earnings forecast at $26,272,443.
In 2028, AVXL is forecast to generate $214,572,188 in earnings, with the lowest earnings forecast at $206,157,593 and the highest earnings forecast at $220,883,135.